• Meeting Highlights in Multiple Myeloma From the 2015 European Hematology Association Annual Congress
  • ASCO 2015 Meeting Highlights
  • New Paradigms and Emerging Frontiers: The Immunotherapy Revolution in Multiple Myeloma
  • Risk Stratification Curriculum
  • Clinical Dialogues™ in Multiple Myeloma
  • Join Today
  • ASH 2014 Meeting Highlights
  • Earn CME Now

What's New

Takeda Submits New Drug Application for Ixazomib for Patients with Relapsed/Refractory Multiple Myeloma
Risk Stratification Curriculum
Diagnoses, Risk Assessment and Adaptive Therapeutic Strategies for Multiple Myeloma Management
This four-part, continuing education curriculum, presented as a Managing Myeloma exclusive, showcases new updates to diagnostic criteria and risk-stratification approaches for the diagnosis and treatment of multiple myeloma.
FAQ Library
Dr. Robert Z. Orlowski answers new FAQs
Expert Perspectives
Expert Perspective in Multiple Myeloma: An Update on the New International Myeloma Working Group (IMWG) Guidelines
George Davatelis, PhD with Sagar Lonial, MD
Journal Club Library
Four recent abstracts with associated “Impact on Practice” are provided.
CE Activity
Annual Meeting HighlightsEHA Annual Meeting Highlights 2015 Live: Advances in Multiple Myeloma Treatment and Management
Sagar Lonial, MD; Paul G. Richardson, MD; Nikhil Munshi, MD; Antonio Palumbo, MD
CE Activity
Annual Meeting HighlightsASCO 2015: Highlights in Multiple Myeloma
Meletios A. Dimopoulos, MD; Sagar Lonial, MD; Donna E. Reece, MD; and Edward A. Stadtmauer, MD
CE Activity
Optimizing Outcomes in Multiple Myeloma: New Regimens and Sequencing Strategies for the Individual Patient
Robert Orlowski, MD, PhD
CE Activity
Clinical Discussion SeriesMultiple Myeloma Response Assessment and Tailoring Therapy
Edward A. Stadtmauer, MD
CE Activity
What Are the Current Trials Most Likely to Change Practice?
Noopur Raje, MD; Christopher Fausel, PharmD, MHA, BCOP; Tiffany Richards, MS, ANP, AOCNP
CE Activity
Evolving Treatment Goals and Addressing the Barrier of High-risk Disease Improved Outcomes
Shaji K. Kumar, MD; R. Donald Harvey III, PharmD, FCCP, BCOP; Beth Faiman, PhD, RN, MSN, APRN-BC, AOCN
CE Activity
What Are the Outstanding Questions Regarding Maintenance and Consolidation?
Noopur Raje, MD; Christopher Fausel, PharmD, MHA, BCOP; Tiffany Richards, MS, ANP, AOCNP